Interventions for paracetamol (acetaminophen) overdose

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 2, 2018, Pages

  Chiew, Angela L ^a,b   Gluud, Christian ^c   Brok, Jesper ^c   Buckley, Nick A ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED CARBON; CIMETIDINE; DIMERCAPROL; FRESH FROZEN PLASMA; INFUSION FLUID; IPECAC; MERCAPTAMINE; METHIONINE; PARACETAMOL; PLACEBO; ANALGESIC AGENT; ANTIDOTE; CHARCOAL;

ACUTE HEPATITIS; CLINICAL TRIAL (TOPIC); CONTINUOUS RENAL REPLACEMENT THERAPY; DECONTAMINATION; DRUG BLOOD LEVEL; DRUG INTOXICATION; FULMINANT HEPATIC FAILURE; HEMODIALYSIS; HEMOPERFUSION; HUMAN; LIVER TOXICITY; LIVER TRANSPLANTATION; MORTALITY; PARACETAMOL POISONING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH LAVAGE; SYSTEMATIC REVIEW; ACUTE LIVER FAILURE; CHEMICALLY INDUCED; DRUG OVERDOSE; INTESTINE ABSORPTION; META ANALYSIS;

ACETAMINOPHEN; ACETYLCYSTEINE; ANALGESICS, NON-NARCOTIC; ANTIDOTES; CHARCOAL; CYSTEAMINE; DIMERCAPROL; DRUG OVERDOSE; GASTRIC LAVAGE; HUMANS; INTESTINAL ABSORPTION; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; METHIONINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33746533423     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003328.pub3     Document Type: Review

References (144)

1. Arefi M, Behnoush B, Pouraziz H, Yousefinejad V. Comparison of oral and intravenous N-acetylcysteine administration in the treatment of acetaminophen poisoning. Scientific Journal of Kurdistan University of Medical Sciences 2013;18(2):36-43. 2990697
2. Bateman DN, Dear JW, Thanacoody HK, Thomas SH, Eddleston M, Sandilands EA, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet 2014;383(9918):607-704. [DOI: 10.1016/S0140-6736(13)62062-0]2990699
3. Douglas AP, Hamlyn AN, James O. Controlled trial of cysteamine in treatment of acute paracetamol poisoning. Lancet 1976;2:111-5. 7626843
4. Eizadi-Mood N, Sabzghabaee AM, Siadat S, Yaraghi A, Shariati M, Gheshlaghi F, et al. Intravenous acetylcysteine versus oral and Intravenous acetylcysteine: does a combination therapy decrease side effects of acetylcysteine?. Pakistan Journal of Medical Sciences 2013;29(1 Suppl):308-11. 2990703
5. Gazzard BG, Willson RA, Weston MJ, Thompson RPH, Williams R. Charcoal haemoperfusion for paracetamol overdose. British Journal of Clinical Pharmacology 1974;1:271-5. 2990705
6. Hamlyn AN, Lesna M, Record CO, Smith PA, Path FRC, Watson AJ. Methionine and cysteamine in paracetamol overdose, prospective controlled trial of early therapy. Journal of International Medical Research 1981;9:226-31. 2990707
7. Hughes RD, Gazzard BG, Hanid MA, Trewby PN, Murray-Lyon IM, Davis M, et al. Controlled trial of cysteamine and dimercaprol after paracetamol overdose. BMJ (Clinical Research Ed.) 1977;2:1395. 2990709
8. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJM, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure. BMJ (Clinical Research Ed.) 1991;303:1026-9. 2990711
9. Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins A, et al. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Annals of Emergency Medicine 2005;45(4):402-8. [MEDLINE: PMID: 15795719]2990713
10. Cumberland Pharmaceuticals. A multi-center, double-blind, randomized, controlled study to determine the efficacy and safety of a new formulation of acetylcysteine injection. clinicaltrials.gov/ct2/show/study/NCT01118663 Date first received: 4 August 2014. 7626845
11. Underhill TJ, Greene MK, Dove AF. A comparison of the efficacy of gastric lavage, ipecacuanha and activated charcoal in the emergency management of paracetamol overdose. Archives of Emergency Medicine 1990;7:148-54. 2990715
12. Bartels S, Sivilotti M, Crosby D, Richard J. Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial. Clinical Toxicology (Philadelphia, Pa.) 2008;46(3):243-9. 2990717
13. Bastaki SMA. Drugs update. Emirates Medical Journal 2006;24(3):245-50. 2990719
14. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning?. Journal of Toxicology. Clinical Toxicology 1999;37(6):759-67. [; JC--NLM: Journal ID:kan, 8213460]7626847
15. Burkhart KK, Janco N, Kulig KW, Rumack BH. Cimetidine as adjunctive treatment for acetaminophen overdose. Human & Experimental Toxicology 1995;14(3):299-304. 2990723
16. Clark RF, Chen R, Williams SR, Johnson CL, Harchelroad F. The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. Journal of Toxicology. Clinical Toxicology 1996;34(2):163-7. 2990725
17. Cooper GM, Le Couteur DG, Richardson D, Buckley NA. A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM: Monthly Journal of the Association of Physicians 2005;98(9):655-60. [MEDLINE: PMID: 16040667]2990727
18. Critchley JA, Dyson EH, Scott AW, Jarvie DR, Prescott LF. Is there a place for cimetidine or ethanol in the treatment of paracetamol poisoning?. Lancet 1983;1(8338):1375-6. 2990729
19. Dordoni B, Willson RA, Thompson RPH, Williams R. Reduction of absorption of paracetamol by activated charcoal and cholestyramine. BMJ (Clinical Research Ed.) 1973;3:86-7. 2990731
20. Douglas AP, Hamlyn AN, James O. Controlled trial of cysteamine in treatment of acute paracetamol (acetaminophen) poisoning. Lancet 1976;1(7951):111-5. 7626849
21. Eguia L, Materson BJ. Acetaminophen-related acute renal failure without fulminant liver failure. Pharmacotherapy 1997;17(2):363-70. 2990735
22. Eyer P, Sprenger M. Oral administration of activated charcoal-sorbitol suspension as first aid in prevention of poison resorption?. Klinische Wochenschrift 1991;69(19):887-94. 2990737
23. Ferner RE. Our poisoned patients. QJM: Monthly Journal of the Association of Physicians 2001;94(3):117-20. 2990739
24. Gawarammana IB, Greene SL, Dargan PI, Jones AL. Australian clinical toxicology investigators collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Annals of Emergency Medicine 2006;47(1):124. 2990741
25. Gazzard BG, Clark R, Borirakchanyavat V, Williams R. A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis. Gut 1974;15(2):89-93. 7626851
26. Gazzard BG, Hughes RD, Chhibber AD, Bennett JR, Murray-Lyon IM, Dordoni B, et al. Proceedings: controlled trial of cysteamine and dimercaprol in the prevention of liver damage after paracetamol overdose. Gut 1975;16(10):839. 2990747
27. Gazzard BG, Henderson JM, William R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 1975;16(8):617-20. 7626853
28. Guay DRP, Hajjar ER. Geriatric pharmacotherapy updates. American Journal Geriatric Pharmacotherapy 2003;1(2):96-100. 2990749
29. Hamlyn AN, Lesna M, Record CO, Smith PA, Watson AJ, Meredith T, et al. Prevention of hepatic necrosis in severe paracetamol (acetaminophen) poisoning: prospective controlled trial of early treatment with cysteamine or methionine [abstract]. Gut 1980;21(2):A448. 2990751
30. Hayes BK. Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose. Annals of Pharmacotherapy 2008;42(6):776-70. 2990753
31. Hershkovitz E, Shorer Z, Levitas A, Tal A. Status epilepticus following intravenous N-acetylcysteine therapy. Israel Journal of Medical Sciences 1996;32(11):1102-4. 2990755
32. Hughes RD, Gazzard BG, Murray-Lyon IM, Williams RS. The use of cysteamine and dimercaprol. Journal of International Medical Research 1976;4(4 Suppl):123-9. [; CN-00702516]2990757
33. Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe?. Lancet 2006;368(9554):2195-6. 2990759
34. Keays RT, Cove C, Forbes A, Alexander GJM, Williams R. Use of late N-acetyl cysteine in severe paracetamol overdose [abstract]. Gut 1989;30(Suppl 10):A1512. [; CN-00255461]2990761
35. Koch A, Trautwein C. N-acetylcysteine on its way to a broader application in patients with acute liver failure. Hepatology (Baltimore, Md.) 2010;51(1):338-40. 2990763
36. Kulig K, Bar-Or D, Cantrill SV, Rosen P, Rumack BH. Management of acutely poisoned patients without gastric emptying. Annals of Emergency Medicine 1985;14(6):562-7. 2990765
37. MacDonald TM. Acetaminophen: risk-management urgently require. Pharmacoepidemiology and Drug Safety 2006;15(6):406-9. 2990767
38. Mann NS. Acetylcysteine for paracetamol-induced hepatic failure. Annals of Internal Medicine 1992;116(Suppl 2):1992. 2990769
39. Mitchell MC, Schenker S, Speeg KV Jr. Selective inhibition of acetaminophen oxidation and toxicity by cimetidine and other histamine H2-receptor antagonists in vivo and in vitro in the rat and in man. Journal of Clinical Investigation 1984;73(2):383-91. 2990771
40. Montoya-Cabrera MA, Escalante-Galindo P, Nava-Juaez A, Terroba-Larios VM, Teran-Hernandez JA. Evaluation of the efficacy of N-acetylcysteine administrated alone or in combination with activated charcoal in the treatment of acetaminophen overdose [Evaluacion de la eficacia de la N-acetilcisteina administrada sola o conbinada con carbon activado en el tratamiento de la sobredosis por acetaminofen]. Gaceta Medica de Mexico 1999;135(3):239-43. 2990773
41. O'Grady JG, Gimson AE, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94(5):1186-92. 2990775
42. Renzi FP, Donovan JW, Martin TG. Concomitant use of activated charcoal and N-acetylcysteine. Annals of Emergency Medicine 1985;14(6):568-72. 2990777
43. Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, et al. Albumin dialysis with a non cell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Annals of Internal Medicine 2013;159(8):522-31. 2990779
44. Spiller HA, Winter ML, Klein-Schwartz W, Bangh SA. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. Journal of Emergency Medicine 2006;30(1):1-5. 2990781
45. Bailey B, McGuigan MA. Management of anaphylactoid reactions to intravenous N-acetylcysteine. Annals of Emergency Medicine 1998;31:710-5.
46. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101. [PUBMED: 7786990]
47. Bernal W, Hyyrylainen A, Gera A, Audimoolam VK, McPhail MJW, Auzinger G, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. Journal of Hepatology 2013;59:74-80.
48. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007; Vol. 26, issue 1:53-77.
49. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9. [PUBMED: 18411040]
50. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive. Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
51. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. Journal of Toxicology. Clinical Toxicology 1999;37(6):753-7.
52. Buckley N, Eddleston M. Paracetamol (acetaminophen) poisoning. BMJ Clinical Evidence 2007;2007:2101.
53. Cairney DG, Beckwith HK, Al-Hourani K, Eddleston M, Bateman DN, Dear JW. Plasma paracetamol concentration at hospital presentation has a dose-dependent relationship with liver injury despite prompt treatment with intravenous acetylcysteine. Clinical Toxicology (Philadelphia, Pa.) 2016;54(5):405-10.
54. Chiew AL, Fountain JS, Graudins A, Isbister GK, Reith D, Buckley NA. Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Medical Journal of Australia 2015;203(5):215-8.
55. Chiew AL, Isbister GK, Duffull SB, Buckley NA. Evidence for the changing regimens of acetylcysteine. British Journal of Pharmacology 2016;81(3):471-81. [DOI: 10.1111/bcp.12789]
56. Chiew AL, Isbister GK, Kirby KA, Page CB, Chan BSH, Buckley NA. Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2). Clinical Toxicology (Philadelphia, Pa.) 2017;55(10):1055-65.
57. Christophersen AB, Levin D, Hoegberg LCG, Angelo HR, Kampmann JP. Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication. British Journal of Clinical Pharmacology 2002;53:312-7.
58. Chyka PA, Seger D, Krenzelok EP, Vale JA, American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: single-dose activated charcoal. Clinical Toxicology 2005;43(2):61-87. [MEDLINE: PMID: 15822758]
59. Clark R, Borirakchanyavat V, Davidson AR, Thompson RP, Widdop B, Goulding R, et al. Hepatic damage and death from overdose of paracetamol. Lancet 1973;1(7794):66-70.
60. Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA, Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand - explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Medical Journal of Australia 2008;188(5):296-301.
61. Dart R, Erdman A, Olson K, Christianson G, Manoguerra A, Chyka P, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clinical Toxicology 2006;44(1):1-18.
62. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. British Medical Journal 1966;2(5512):497-9.
63. DeMets DL. Practical aspects in monitoring: a brief review. Statistics in Medicine 1987;6(7):753-60.
64. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
65. Doyon S, Klein-Schwartz W. Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose. Academic Emergency Medicine 2009;16(1):34-9.
66. Duffull SB, Isbister GK. Predicting the requirement for N-acetylcysteine in paracetamol poisoning from reported dose. Clinical Toxicology (Philadelphia, Pa.) 2013;51(8):772-6.
67. Eddleston M, Juszczak E, Buckley NA, Senarathna L, Mohamed F, Dissanayake W, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 2008;371(9612):579-87.
68. Egger M, Davey GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ (Clinical Research Ed.) 1997;315:629-34.
69. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About Cochrane (Cochrane Review Groups (CRGs)) 2017, Issue 5. Art. No.: LIVER.
70. Gosselin S, Juurlink DN, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, EXTRIP Workgroup. Extracorporeal treatment for acetaminophen poisoning: recommendations from the EXTRIP workgroup. Clinical Toxicology (Philadelphia, Pa.) 2014;52(852):856-67.
71. Green R, Grierson R, Sitar DS, Tenenbbein M. How long after drug ingestion is activated charcoal still effective?. Journal of Toxicology. Clinical Toxicology 2001;39(6):601-5.
72. Green JL, Heard KJ, Reynolds KM, Albert D. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta-analysis. Western Journal of Emergency Medicine 2013;14(3):218-26.
73. Gunnell D, Hawton K, Murray V, Garnier R, Bismuth C, Fagg J, et al. Use of paracetamol for suicide and non-fatal poisoning in the UK and France: are restrictions on availability justified?. Journal of Epidemiology and Community Health 1997;51:175-9.
74. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2008;336:924-6.
75. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
76. Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335(8705):1572-3.
77. Heard K, Rumack BH, Green JL, Bucher-Bartelson B, Heard S, Bronstein AC, et al. A single-arm clinical trial of a 48-hour intravenous N-acetylcysteine protocol for treatment of acetaminophen poisoning. Clinical Toxicology 2014;52:512-8.
78. Heard K, Newton A. Paracetamol overdose. BMJ Best Practice: bestpractice.bmj.com last updated: 28 March 2017:1-46.
79. Henry J, Volans G. ABC of poisoning. Analgesics: II - paracetamol. British Medical Journal (Clinical Research Ed.) 1984;289(6449):907-8.
80. Higgins RM, Goldsmith DJ, MacDiarmid-Gordon A, Taberner D, Venning MC, Ackrill P. Treating paracetamol overdose by charcoal haemoperfusion and long-hours high-flux dialysis. QJM: Monthly Journal of the Association of Physicians 1996;89(4):297-306.
81. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
82. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org.
83. Higgins JPT, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. [Available from www.cochrane-handbook.org.]
84. Jakobsen J, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014;14:120.
85. Jones AL. Mechanism of action and value of N acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. Journal of Toxicology. Clinical Toxicology 1998;36:277-85.
86. Kao LW, Kirk MA, Furbee RB, Mehta NH, Skinner JR, Brizendine EJ. What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning?. Annals of Emergency Medicine 2003;42(6):741-50.
87. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9. [PUBMED: 11730399]
88. Koch-Weser J. Acetaminophen. New England Journal of Medicine 1976;295(23):1297-300.
89. Krenzelok EP, McGuigan M, Lheur P, Manoguerra AS. Position paper: Ipecac syrup. Journal of Toxicology. Clinical Toxicology 2004;42(2):133-43. [MEDLINE: PMID: 15214617]
90. Kwan D, Bartle WR, Walker SE. Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Digestive Diseases and Sciences 1995;40(9):1951-5.
91. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology (Baltimore, Md.) 2004;40(1):6-9. [MEDLINE: PMID: 15239078]
92. Lee WM, Larson AM, Todd Stravitz R. AASLD position paper: the management of acute liver failure: update 2011. www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf (accessed June 2017).
93. Liisanantti J, Kaukoranta P, Martikainen M, Ala-Kokko T. Aspiration pneumonia following severe self-poisoning. Resuscitation 2003;56(1):49-53. [MEDLINE: PMID: 12505738]
94. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3; PUBMED: 23235689]
95. Mant TG, Tempowski JH, Volans GN, Talbot JC. Adverse reactions to acetylcysteine and effects of overdose. British Medical Journal (Clinical Research Ed.) 1984;289(6439):217-9. [PMID: 6234965]
96. Marks DJB, Dargan PI, Archer JRH, Davies CL, Dines AM, Wood DM, et al. Outcomes from massive paracetamol overdose: a retrospective observational study. British Journal of Clinical Pharmacology 2017;83:1163-5.
97. McElhatton PR, Sullivan FM, Volans GN. Paracetamol overdose in pregnancy analysis of the outcomes of 300 cases referred to the Teratology Information Service. Reproductive Toxicology (Elmsford, N.Y.) 1997;11(1):85-94.
98. Medicines and Healthcare products Regulatory Agency. Treating paracetamol overdose with intravenous acetylcysteine: new guidance, 2012. www.gov.uk/drug-safety-update/treating-paracetamol-overdose-with-intravenous-acetylcysteine-new-guidance (accessed 20 May 2016).
99. Mitchell JR, Thorgeirrson SS, Potter WZ. Acetaminophen induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clinical Pharmacology and Therapeutics 1974;16(4):676-84.
100. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
101. Morgan O, Griffiths C, Majeed A. Impact of paracetamol pack size restrictions on poisoning from paracetamol in England and Wales: an observational study. Journal of Public Health 2005;27(1):19-24. [MEDLINE: PMID: 15637104]
102. O'Grady JG. Paracetamol-induced acute liver failure. Journal of Hepatology 1997;26 (Suppl):41-6.
103. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Journal of Clinical Pharmacology 1988;34(1):77-82.
104. Park BK, Dear JW, Antoine DJ. Paracetamol (acetaminophen) poisoning. BMJ Clinical Evidence 2015;2015:pii: 2101.
105. Prescott LF, Wright N. The effects of hepatic and renal damage on paracetamol metabolism and excretion following overdosage.: A pharmacokinetic study. British Journal of Pharmacology 1973;49(4):602-13.
106. Prescott LF, Sutherland GR, Park J, Smith IJ, Proudfoot AT. Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning. Lancet 1976;2(7977):109-13.
107. Prescott LF, Illinngworth RN, Chrichley JAJ, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. British Medical Journal 1979;2:1097-100.
108. Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. British Journal of Clinical Pharmacology 1980;10:291S-8S.
109. Prescott K, Stratton R, Freyer A, Hall I, Le Jeune I. Detailed analyses of self-poisoning episodes presenting to a large regional teaching hospital in the UK. British Journal of Clinical Pharmacology 2009;68(2):260-8.
110. Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Annals of Internal Medicine 2016;164(11):724-32.
111. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
112. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
113. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975;55:871-6.
114. Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clinical Toxicology 2012;50:91-8.
115. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clinical Toxicology (Philadelphia, Pa.) 2009;47(2):81-8.
116. Savović J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38. [PUBMED: 22945832]
117. Savović J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technology Assessment 2012;16(35):1-82. [PUBMED: 22989478]
118. Schmidt LE, Dalhoff K. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. British Journal of Pharmacology 2001;51(1):87-91.
119. Schmidt LE, Knudsen TT, Dalhoff K, Bendtsen F. Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. Lancet 2002;360(9340):1151-2.
120. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
121. Senarathna SG, Sri RS, Buckley N, Fernandopulle R. A cost effectiveness analysis of the preferred antidotes for acute paracetamol poisoning patients in Sri Lanka. BMC Clinical Pharmacology 2012;12(1):6.
122. Shiago K, Watson I, Reidenberg MM. Application to change the status of methionine or N-acetylcysteine on the model list, 2011. www.who.int/selection_medicines/committees/expert/18/applications/Delete_Methionine.pdf (accessed 20 May 2016).
123. Skoog M, Saarimäki JM, Gluud C, Sheinin M, Erlendsson K, Aamdal S, et al. Transparency and Registration in Clinical Research in the Nordic Countries. Oslo (Norway): Nordic Trial Alliance, NordForsk, 2015.
124. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). New England Journal of Medicine 1988;319(24):1557-62.
125. Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Annals of Emergency Medicine 1991;20(10):1058-63.
126. Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterology Clinics of North America 1995;24(4):1047-64.
127. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86. [PUBMED: 18824467]
128. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66. [PUBMED: 20865104]
129. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 20 May 2016).
130. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
131. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995;346(8974):547-52.
132. Vale JA, Kulig K, American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position statement: gastric lavage. Journal of Toxicology. Clinical Toxicology 2004;42(7):933-43. [MEDLINE: PMID: 15641639]
133. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
134. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86. [PUBMED: 20042080]
135. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology 2017;17(1):39.
136. Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased international normalized ratio by reducing functional factor VII. Therapeutic Drug Monitoring 2000;22(6):742-8.
137. Williamson K, Wahl MS, Mycyk MB. Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning. American Journal of Therapeutics 2013;20(1):37-40.
138. Wolf SJ, Heard K, Sloan EP, Jagoda AS. Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose. Annals of Emergency Medicine 2007;50:292-313.
139. Woo OF, Mueller PD, Olson KR, Anderson IB, Kim SY. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Annals of Emergency Medicine 2000;35(4):363-8.
140. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5. [PUBMED: 18316340]
141. Yeates PJA, Thomas SHL. Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose. British Journal of Clinical Pharmacology 2000;49(1):11-4.
142. Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-induced hepatotoxicity: a comprehensive uUpdate. Journal of Clinical and Translational Hepatology 2016;4(2):131-42.
143. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdoses. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003328]
144. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database of Systematic Reviews 2006, Issue 2. [; DOI: 10.1002/14651858.CD003328.pub2; JC--NLM: Journal ID:100909747]